Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer

Next Previous
Trial Profile

Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olaparib (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms TOPARP; TOPARP-A; TOPARP-B

    • Most Recent Events

    • 10 Apr 2021 Results of exploratory analysis investigating the predictive value of an HRR function assay detecting RAD51 foci by immunofluorescence in tumor biopsies presented at the 112th Annual Meeting of the American Association for Cancer Research
    • 02 Dec 2019 Results presented in The Institute of Cancer Research Media Release.
    • 02 Dec 2019 According to The Institute of Cancer Research media release, this trial was funded in part by olaparib's manufacturer, AstraZeneca, plus by Cancer Research UK, Prostate Cancer UK, the Prostate Cancer Foundation, Movember and the Experimental Cancer Medicine Centre (ECMC) Network.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top